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ABSTRACT:  29 
 30 
The discovery and detailed characterization of several new solid forms of a novel selective inhaled JAK-31 
STAT inhibitor are described. Using a holistic cocrystallization screen approach to explore its 32 
formulation landscape, we decrease the risk of future potential development failures due to a nonoptimal 33 
pharmacokinetic lung profile or undesired lung effects in humans. 34 
 35 
..36 
1. INTRODUCTION 37 
 38 
Compound 1 is a novel and selective Janus kinase-signal transducers and activation of transcription 39 
(JAK-STAT) inhibitor. JAKs belong to one intracellular subgroup of the nonreceptor protein tyrosine 40 
kinases involved in cell growth, survival, development, and differentiation of a variety of cells, critically 41 
important for immune and hematopoietic cells. Type I and II cytokine receptors are constitutively 42 
associated with JAKs, and the binding of ligand (cytokine) initiates a transphosphorylation cascade: 43 
receptor-JAK-STAT. Phosphorylated STATs dissociate from the receptor, dimerize, translocate to the 44 
nucleus, and bind to specific sequences to regulate the expression of target genes.1,2 45 
Given the importance of JAKs inhibitors (“jakinibs”) to modulate cytokine signaling, they may be useful 46 
for the treatment of various diseases or conditions in which the functions of the innate and/or adaptive 47 
immune system are involved.3−5 JAK inhibitors are currently being evaluated in a diverse range of 48 
disorders (rheumatoid arthritis, psoriasis, inflammatory bowel disease, and myeloproliferative 49 
disorders), and many more trials are underway in other autoimmune disorders (juvenile idiopathic 50 
arthritis, ankylosing spondylitis, systemic lupus erythematosus, Sjögren’s syndrome), chronic kidney 51 
disease and diabetic nephropathy, breast cancer, lymphoma, and the prevention of graft rejection. For a 52 
review of the pharmaceutical intervention of the JAK/STAT pathway, see references 6−9. 53 
In view of the numerous conditions and disorders susceptible to “jakinibs” treatment, it is expected that 54 
the new compounds, new forms of an existing compound, and new routes of administration for these 55 
compounds provide significant therapeutic benefits to a variety of patients. 56 
When developing poorly soluble drugs for oral inhaled delivery, special caution needs to be paid to the 57 
design of the inhalation product. For inhaled compounds, the mean absorption time from the lung is not 58 
usually correlated to a single physicochemical property,10 but there is some evidence that the absorption 59 
from the lung of a poorly soluble neutral inhaled compound into the central circulation may be 60 
correlated to dissolution.11 Controlling the dissolution rate is therefore of utmost importance to achieve 61 
an optimal lung pharmacokinetic profile. When a poorly soluble inhaled compound dissolves too fast, 62 
the desired effect can be too short, assuming neither permeability nor transporter cell uptake is limiting 63 
the absorption. On the other hand, if it dissolves too slowly, the compound might accumulate in the lung 64 
and be a reason for unexpected adverse effects. The rate and extent of the absorption from the lung (and 65 
the safety profile) of a poorly soluble inhaled compound will depend (excluding physiological 66 
differences or disease-related changes) on many factors, mainly the physicochemical properties of the 67 
delivered drug and its material properties (solubility, dissolution rate, size, shape, charge, crystallinity, 68 
and chemical composition). It is generally accepted that any undissolved particulate material in the lungs 69 
can result in adaptive adverse/ tox effects.12 It is therefore advisable to explore the formulation 70 
landscape as early as possible in the discovery phase so several forms (salts, cocrystals, solvates, 71 
polymorphs···), with different physicochemical properties, are available to the team for in vivo 72 
assessment and in this way decrease the risk of costly surprises during the following development phase. 73 
In this paper, we describe the discovery and detailed characterization of several new forms of 1 using a 74 
holistic approach to explore the formulation landscape of 1 to decrease the risk of potential development 75 
failures due to a nonoptimal pharmacokinetic lung profile or undesired lung effects in humans. To do so, 76 
we selected a list of 20 coformers from a database containing more than 2300 compounds, including 860 77 
products regarded as “safe” by the FDA (GRAS list). The selection was performed according to the 78 
virtual prediction results in combination with a factor obtained from a multiparameter assessment, which 79 
included melting point of the coformers, safety and tox profile of the coformers, and solubility in water 80 
stipulation. We gave an important relative weight to the safety/tox profile for each coformer, since the 81 
new forms discovered were intended for human use. The safety/tox profile was performed as a 82 
combination of an in house AZ in silico assessment, experimental safety end points from multiple 83 
databases, and different structural alerts. The resulting safety/tox profile contained information about 84 
hERG activity, phospholipidosis, AhR, Nav1.5, CaV1.2, potential to form reactive metabolites, genotox, 85 
AMES, carcinogenicity, mouse lymphoma, chromosomal aberration and micro nucleus, among others. 86 
The solubility stipulation was assigned a high contribution factor to the multiparameter assessment since 87 
it had been shown previously that the solubilities of compounds formulated as cocrystals increase in 88 
proportion to the solubility of the coformer.13,14 The experimental cocrystal screen was then performed 89 
on 20 coformers with a good chance of forming a cocrystal with different, and hopefully better, 90 
dissolution rate profiles (compared to the free base 1), which are stable and safe for human oral inhaled 91 
dosing. 92 
93 
2. MATERIALS AND METHODS 94 
 95 
2.1. Experimental Screen. A comprehensive cocrystal screening has been conducted by using different 96 
combinations of solvents at several concentrations and temperatures, with variable cooling rates, in both 97 
thermodynamic and kinetic conditions. Solubility of 1 was initially determined in 36 solvents, and 98 
accordingly drop grinding, reaction crystallization, and solved mediated transformation techniques were 99 
applied to each 1/coformer combination. All solids were analyzed by powder X-ray diffraction (PXRD) 100 
to assess the formation of a new solid form. 101 
 102 
2.2. Virtual Cocrystal Screening. For each compound, the molecule was drawn in an extended 103 
conformation and energy minimized using the molecular mechanics methods implemented in 104 
TorchLite.15 Gaussian 09 was used to optimize the geometry and calculate the MEPS on the 0.002 Bohr 105 
Å−3 electron density isosurface using density functional theory (DFT) and a B3LYP/6-31G* basis 106 
set.16 The MEPS was converted into SSIPs using in-house software.17 107 
 108 
2.3. Powder X-ray Diffraction (PXRD). Powder X-ray diffraction patterns were obtained on a 109 
PANalytical X’Pert PRO MPD diffractometer in transmission configuration using Cu Kα1+2 radiation 110 
(λ = 1.5418 Å) with a focalizing elliptic mirror, a PIXcel detector working at a maximum detector’s 111 
active length of 3.347°. Flat geometry has been used for routine samples sandwiched between 112 
lowabsorbing films (polyester of 3.6 μm of thickness) measuring 2θ/θ scans from 2 to 40° in 2θ with a 113 
step size of 0.026° and a measuring time of 80−300 s per step. The indexation of the PXRD diagrams 114 
was carried out by means of Dicvol04.18 The unit cell parameters were refined by Le Bail fit19 using 115 
the Fullprof program,20 and the most probable space groups were determined from the systematic 116 
absences. 117 
 118 
2.4. Differential Scanning Calorimetry (DSC). Differential scanning calorimetry analyses were 119 
carried out by means of a Mettler- Toledo DSC-822e calorimeter. Experimental conditions: aluminium 120 
crucibles of 40 μL volume, atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10 121 
°C/min. The calorimeter was calibrated with indium of 99.99% purity. (m.p.: 156.8 °C ΔH: 28.68 J/g). 122 
 123 
2.5. Thermogravimetric Analysis (TGA). Thermogravimetric analyses were performed on a Mettler-124 
Toledo TGA-851e thermobalance. Experimental conditions: alumina crucibles of 70 μL volume, 125 
atmosphere of dry nitrogen with 50 mL/min flow rate, heating rate of 10 °C/min. 126 
2.6. X-ray Crystallographic Analysis. The single crystal structures were collected using a D8 Venture 127 
system equipped with a multilayer monochromator and a Mo or Cu microfocus (λ = 0.71073 Å or λ = 128 
1.54178 Å) has been used too. Frames were integrated with the Bruker SAINT software package using a 129 
SAINT algorithm. Data were corrected for absorption effects using the multiscan method (SADABS).21 130 
The structures were solved and refined using the Bruker SHELXTL Software Package, a computer 131 
program for automatic solution of crystal structure and refined by fullmatrix least-squares method with 132 
ShelXle Version 4.8.0, a Qt graphical user interface for the SHELXL computer program.22 133 
134 
3. RESULTS AND DISCUSSION 135 
 136 
3.1. Virtual Cocrystal Screen. The selection of the coformers used in the cocrystal screen was based on 137 
the computational cocrystal screen method developed by Prof. Hunter, which has been validated using 138 
experimental cocrystal data extracted from the literature.23,24 This computational method has been 139 
recently applied to several active pharmaceutical ingredients (APIs) with a remarkable success by 140 
Hunter’s group, including nalidixic acid,25 griseofulvin and spironolactone,26 and some of us have 141 
recently used it to guide the discovery of new cocrystals of zafirlukast27,28 and sildenafil.29 The in 142 
silico method is based on the calculation of a cocrystal pairing energy between the API and the 143 
coformer. This calculation is performed by using the surface site interaction points (SSIPs), which can 144 
be extracted from molecular electrostatic potential surfaces computed at the DFT level of computation 145 
as described in reference 17 or estimated with a faster method based on the molecular electrostatic 146 
potential surfaces (MEPS) calculated from MMFF94 atomic partial charges.30,31 We have followed the 147 
methodology at the DFT level of computation with compound 1, and 20 coformers have been chosen 148 
among the 100 coformers with the highest probability of cocrystallization from a database containing 149 
more than 2400 compounds (including 860 products from the GRAS list) according to the virtual 150 
prediction ranking. Table 2 shows the 20 coformers along with their corresponding ΔE values. 151 
The so-called “rule of 3” is frequently used to predict the outcome of a salt or a cocrystal. The rule is 152 
based on the calculation of the difference of pKa between the protonated base and the acid. When this 153 
value is less than 0, a cocrystal is expected, and when it is greater than 3 a molecular salt is the expected 154 
form. However, with intermediate values predictions are less reliable.32,33 Recently, a linear 155 
relationship between the ΔpKa value and the probability of salt/cocrystal formation has been derived by 156 
Cruz-Cabeza from more than 6000 component systems (eq 1).34 This equation allows a statistical 157 
prediction of proton transfer (P, %) around the “salt-cocrystal continuum” region of ΔpKa ≈ 1, which 158 
lies in a range of values between −1 and 4. We have applied this simple calculation to the coformers 159 
chosen for the screening in order to assess the probability of proton transfer, and values can be found in 160 
Table 2. 161 
 (1) 162 
Given that 1 contains a pyrimidine and a benzoxazolinone group (measured pKa values of 5.9 and 8.9 163 
respectively) and most of the coformers are carboxylic acids and strong organic bases, according to the 164 
pKa rule, both salts and cocrystals were expected to be obtained, although with a higher probability of 165 
salt formation. However, since both types of multicomponent solid forms could improve hysicochemical 166 
properties, no coformers were filtered according to proton transfer probability in order to increase 167 
diversity of crystal forms.  168 
3.2. Experimental Salt/Cocrystal Screen. A total number of 130 experiments using selected 169 
combinations between 36 solvents and 20 coformers have been conducted, distributed mainly in two 170 
methodologies (drop grinding and reaction crystallization techniques) to test the formation of cocrystals 171 
with compound 1. Our high-throughput methodology consists of the initial and qualitative solubility 172 
assessment of compound 1 and each of the 20 coformers in 36 solvents.36 Then, four solvents were 173 
selected according to the solubility information, which is a key issue for a rational design of the 174 
screening conditions and that allows the optimized exploration of the cocrystallization landscape for 175 
each 1/conformer combination with the highest probability of success and the lowest number of 176 
experiments. Evidence of cocrystallization is detected by measuring PXRD diffractograms and DSC 177 
thermograms for each solid obtained during the screen. When it has not been possible to solve the 178 
crystal structures, 1H NMR has been used to determine API/conformer stoichiometry, and 179 
diffractograms have been indexed when possible to confirm the crystal form purity. 180 
 181 
3.3. New Solid Forms of Compound 1. During the solubility determination of compound 1 in 36 182 
solvents in a range of 30−90 °C, new solvate forms of compound 1 have been discovered and 183 
characterized with formic acid (Form A), DMF (Form B), DMSO (Form C), and acetic acid (Forms D-1 184 
to D-4). Compound 1 is soluble at 25 °C in formic acid, DMF, DMSO, and dimethylamine (40% in 185 
water). At 40 °C, it is soluble in acetic acid. It is insoluble in methanol, ethanol, isopropanol, butanol, 186 
ethylene glycol, ACN, MEK, acetone, MiBK, water, pentane, heptane, cyclohexane, toluene, xylene, 187 
AcOEt, diethyl ether, THF, dimethyl ethylene glycol, diisopropyl ether, dioxane, 1,2-dichlorothane, 188 
chloroform, benzylalcohol, diethylamine, triethylamine, NH3 (2 M in MeOH), dimethylamine (2 M in 189 
MeOH), mixture of MeOH/ DCM (10:90) and trifluoroethanol. The solutions obtained °C until 190 
crystallization of a solid. The new forms have been isolated and characterized by means of DSC, 1H 191 
NMR, PXRD, and TGA in some cases. All of them show a 1:1 stoichiometry except the system formed 192 
by compound 1 and acetic acid, which is a multicomponent solid forms set composed of four different 193 
modifications showing polymorphism and different stoichiometries (1:1, 1:2, and 1:4). A complete 194 
characterization of each new form is included in the Supporting Information. 195 
All new solvate forms were heated up to a temperature in which the desolvation was ensured under 196 
nitrogen atmosphere, then cooled down to room temperature and measured by PXRD, and in all cases 197 
the same anhydrous crystal form of compound 1 was obtained. These results together with the fact that 198 
no new anhydrous forms of compound 1 were discovered during the solid forms screening suggested 199 
initially that compound 1 does not present polymorphism. However, one of the acetic acid solvates 200 
(Form D-1) shows a DSC thermogram with a melting point, once the acetic acid is removed on heating, 201 
20 °C lower than the previously observed for compound 1 (Figure 5), which suggests that another 202 
metastable polymorph of compound 1 can exist although with a rapid conversion to the stable one since   203 
it has not been isolated so far. 204 
 205 
3.4. New Salts/Cocrystals of Compound 1. New multicomponent forms of compound 1 have been 206 
identified after the cocrystal screening with 8 out of the 20 coformers tested: 1,4,8,11-207 
tetrazacyclotetradecane, 3,5-dinitrobenzoic acid, gallic acid, orotic acid, 5-nitroisophthalic acid, 3,5-208 
dihydroxybenzoic acid, 1-methyl-2-pyrrolidone, and 4-nitrobenzenesulfonic acid. Some of these new 209 
phases were isolated as different polymorphs and solvates. In those cases where crystal structure has not 210 
been solved, the definition of the form as a salt or a cocrystal has been done based on the probability of 211 
proton transfer determined with eq 1. 212 
• 1:1,4,8,11-Tetrazacyclotetradecane salt (Form I). It has been obtained by reaction crystallization. A 213 
2:1 stoichiometry has been deduced according to 1H NMR and single X-ray diffraction. 214 
• 1:3,5-Dinitrobenzoic acid salt isopropanol solvate (Form II-A): it has been obtained by reaction 215 
crystallization in IPA. A 1:1:2 stoichiometry has been deduced according to single X-ray diffraction. 216 
• 1:3,5-Dinitrobenzoic acid salt (Form II-B): it has been obtained by reaction crystallization in acetone. 217 
A 1:1 stoichiometry has been deduced according to 1H NMR. 218 
• 1:3,5-Dinitrobenzoic acid salt (Form II-C): it has been obtained by reaction crystallization in THF. A 219 
1:1 or 1:1.5 stoichiometry can be deduced according to 1H NMR. 220 
• 1:3,5-Dinitrobenzoic acid salt dioxane solvate (Form IID): it has been obtained by reaction 221 
crystallization in dioxane. A 1:1:1 stoichiometry has been deduced according to 1H NMR. 222 
• 1:3,5-Dinitrobenzoic acid salt (Form II-E): it has been obtained by slurry in water. A 1:1 stoichiometry 223 
has been deduced according to 1H NMR. 224 
• 1:Gallic acid salt THF solvate (Form III): It has been obtained by reaction crystallization in THF. A 225 
1:1:1 stoichiometry has been deduced according to 1H NMR. The XRD pattern shows broad 226 
diffraction peaks (Figure 6). Further attempts to obtain higher crystallinity solids were unsuccessful. 227 
• 1:Orotic acid salt (Form IV-A): it has been obtained by slurry in IPA (4 days), acetone (4 days), THF 228 
(4 days) or dioxane (7 days). A 1:1 stoichiometry has been deduced according to 1H NMR. 229 
• 1:Orotic acid salt (Form IV-B): it has been obtained not pure, as a mixture with Form IV-A, by slurry 230 
in dioxane (4 days). 231 
• 1:Orotic acid salt (Form IV-C): it has been obtained not pure, as a mixture with Form IV-A, by slurry 232 
in water (4 days). 233 
• 1:5-Nitroisophthalic acid salt (Form V-A): it has been obtained by reaction crystallization in IPA (4 234 
days). A 1:1 stoichiometry has been deduced according to 1HRMN. 235 
• 1:5-Nitroisophthalic acid salt (Form V-B): it has been obtained by reaction crystallization in acetone 236 
(4 days). A 1:1 stoichiometry has been deduced according to 1HRMN. 237 
• 1:5-Nitroisophthalic acid salt (Form V-C): it has been obtained by heating up to 215 °C form V−B in a 238 
TGA crucible. A 1:1 stoichiometry has been deduced according to 1H-RMN. 239 
• 1:5-Nitroisophthalic acid salt dioxane solvate (Form VD): it has been obtained by reaction 240 
crystallization in dioxane (4 days). 241 
• 1:5-Nitroisophthalic acid salt (Form V-E): it has been obtained by heating up to 230 °C form V-D in a 242 
TGA instrument. A 1:1 stoichiometry has been deduced according to 1H-RMN. 243 
• 1:3,5-Dihydroxybenzoic acid salt (Form VI): It has been obtained by reaction crystallization in water. 244 
A 1:1 stoichiometry has been deduced according to 1H NMR. 245 
• 1:1-Methyl-2-pyrrolidone cocrystal (Form VII): It has been obtained by slurry in THF or heptane. A 246 
1:1 stoichiometry has been deduced according to 1H NMR. 247 
• 1:4-Nitrobenzenesulfonic acid salt (Form VIII): It has been obtained by reaction crystallization in 248 
ipOH, acetone, THF, dioxane, or water. A 1:1 stoichiometry has been deduced according to 1H NMR 249 
A comparison of the PXRD of the new multicomponent forms of compound 1 obtained as a single form 250 
is shown in Figure 6. 251 
A comparison of the PXRD of the different forms abovementioned for 1:3,5-dinitrobenzoic acid is 252 
shown in Figure 7. 253 
A comparison of the PXRD of the different forms abovementioned for 1:orotic acid is shown in Figure 254 
8. 255 
A comparison of the PXRD of the different forms abovementioned for 1:5-nitroisophthalic acid is 256 
shown in Figure 9.  257 
When possible, the PXRD diagrams of the new forms were indexed, and the results are shown in Table 258 
3. The rest of the forms could not be obtained in pure form, which hindered the indexing process. 259 
3.5. Single Crystal Structures. Crystals of forms I, II-A, DMF solvate, and acetic acid hybrid salt-260 
cocrystal suitable for SCXRD analysis have been obtained, and their crystallographic data are 261 
summarized in Table 4. 262 
3.5.1. Form I. 1:1,4,8,11-Tetrazacyclotetradecane (cyclam) salt crystallizes with one molecule of 1 and 263 
half molecule of 1,4,8,11-tetrazacyclotetradecane in the asymmetric unit. The ΔpKa value is 2.0 (pKa of 264 
the coformer is 10.9) with a probability of salt formation of P = 62%, and the SCXRD data confirm 265 
(from a difference synthesis and refined with an isotropic temperature factor) the location of two 266 
hydrogens bonded to the coformer’s nitrogen. In the structure, every molecule of 1 anion interacts with a 267 
molecule of tetrazacyclotetradecane bis cation and another molecule of 1 via the oxazolidinone ring 268 
through charged assisted hydrogen bonds and electrostatic interactions. Moreover, 269 
tetrazacyclotetradecane molecules are sandwiched between molecules of 1 using two out of the four 270 
amine nitrogens to interact with the 1 oxazolidinone nitrogens. 271 
 272 
3.5.2. Acetic Acid Hybrid Salt-Cocrystal. This multicomponent solid form crystallizes with one 273 
molecule of 1 and four molecules of acetic acid in the asymmetric unit. The solid form is a hybrid salt-274 
cocrystal37,38 since one molecule of acetic acid has transferred the acidic proton to the pyrimidine 275 
nitrogen establishing a charge assisted hydrogen bond and at the same time neutral acetic acid molecules 276 
are also present in the crystal structure. Since the ΔpKa value is 1.1 (pKa of the acetic acid is 4.8), the 277 
probability of salt formation is P = 47%, and thus this structure could be considered as an example of the 278 
“salt-cocrystal continuum”. Cocrystals and salts formed between carboxylic acids and N-heterocycles 279 
have been analyzed in the literature, and it has been suggested that the formation of unexpected hybrid 280 
salt-cocrystals can be produced because carboxylate moieties are not totally satisfied by a single 281 
hydrogen-bond donor, which makes necessary the presence of neutral carboxylic acids in the crystal 282 
structure.39 In the crystal structure, both C−O distances in the acetate molecule are practically the same 283 
(1.263(3) Å and 1.263(2) Å), and the transferred proton well located (and refined with an isotropic 284 
temperature factor) on the pyrimidine nitrogen, discarding a potential disorder. Three other acetic acid 285 
molecules satisfy the two amide hydrogen bond donors and the CO acceptor groups of 1, which could be 286 
anticipated by the position and magnitude of the SSIPs of the isolated compound 1 molecule (Figure 287 
11). 288 
 289 
3.5.3. DMF Solvate. The DMF solvate crystallizes with one molecule of 1 and one of DMF in the 290 
asymmetric unit. In the structure, molecules of 1 interact in a zigzag arrangement with intermolecular 291 
contacts between the oxazolidinone amide and the aminopyrimidine groups. In principle, two 292 
configurations are possible: amide/amide plus aminopyrimidine/aminopyrimidine or mixed 293 
amide/aminopyrimidine interactions. Interestingly,  the interaction energy of both configurations are 294 
very similar when estimated both by pairing H-bond parameters calculated from MMFF94 atomic 295 
partial charges (E = Σij εiεj = 36.7 and 37.2 kJ/mol respectively) and from DFT MEPs (E = Σij εiεj = 296 
40.5 and 42.7 kJ/mol respectively), the observed configuration being the one with the predicted highest 297 
interaction energy. DMF molecules complete the sphere of coordination of 1 by establishing H-bond 298 
interactions with the second best donor of 1, Figure 12. 299 
 300 
3.5.4. Form II-A. Form II-A crystallizes with one molecule of 1, one of 3,5-dinitrobenzoic acid, and two 301 
of isopropanol in the asymmetric unit. Again the crystal form corresponds to a salt in which the 302 
pyrimidine ring is protonated and interacts strongly with the carboxylate moiety of the coformer. In the 303 
structure only one of the strong SSIPs of 1 (the oxazolidinone NH) is not involved in any relevant 304 
intermolecular interaction. 305 
 306 
3.6. Polymorphism in the Multicomponent Crystals of 1. Although it has been traditionally suggested 307 
that polymorphism in multicomponent crystals is a phenomenon observed with less frequency that in 308 
single component crystals,40 it has been put in doubt,41 and recently some of us discovered new 309 
cocrystals of agomelatine with polymorphism increasing the list of compounds showing cocrystal 310 
polymorphism.42 The present case study shows polymorphism in at least two of the new salts of 1 with 311 
3,5-dinitrobenzoic acid and 5-nitroisophthalic acid, which we believe can contribute to new data to 312 
enrich the debate about whether multicomponent crystals are less prone to exhibit polymorphism than 313 
single component crystals. In particular, solvates of the 1:3,5- dinitrobenzoic salt II-A and II-D show a 314 
DSC thermogram with recrystallization after desolvation of an anhydrous form with a different melting 315 
point that anhydrous forms II-B, II-C, and II-E, demonstrating that this salt exists in at least four 316 
different polymorphs and two solvates (Figure 14). A similar behavior is observed in solvated salts with 317 
5- nitroisophthalic acid in which forms V-B and V-D are desolvated upon heating in a DSC experiment 318 
exhibiting a recrystallization exothermic process which produced two different solid forms according to 319 
the melting points. 320 
321 
4. CONCLUSIONS 322 
By using a holistic cocrystallization screen approach, we have explored the formulation landscape of the 323 
first inhaled JAKSTAT inhibitor 1 and have generated multiple solid forms covering a broad 324 
physicochemical space and therefore decreased the risk of future potential development failures due to a 325 
nonoptimal pharmacokinetic lung profile or undesired lung effects in humans. This comprehensive 326 
cocrystal/salts screening was conducted using different combinations of solvents at several 327 
concentrations and temperatures, with variable cooling rates, in both thermodynamic and kinetic 328 
conditions. Solubility of 1 was initially determined in 30 solvents, and accordingly drop grinding, 329 
reaction crystallization, and slurry techniques were applied to each 1/conformer combination. Despite 1 330 
not showing polymorphism, eight new forms of 1 (and multiple solvates) were identified: 1,4,8,11- 331 
tetrazacyclotetradecane, 3,5-dinitrobenzoic acid, gallic acid, orotic acid, 5-nitroisophthalic acid, 3,5-332 
dihydroxybenzoic acid, 1-methyl-2-pyrrolidone, and 4-nitrobenzenesulfonic acid. Many of these new 333 
phases were isolated as different polymorphs and solvates. All solids were analyzed by PXRD to assess 334 
the formation of a new solid form. After a careful comparison and risk assessment of the in vivo 335 
pharmacokinetics, lung deposition, clearance, pulmonary response, effect and safety profile, “the best” 336 
one will be progressed as the candidate drug into human trials. We are now assessing their in vivo 337 
potential where the most promising ones will be scaled up and brought forward to the next phase, and 338 
this will be the subject of a future publication. 339 
340 
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Legends to figures 460 
 461 
Fig. 1 Molecular structure of compound 1. 462 
 463 
Fig. 2 SSIPs calculated for 1. Blue spheres correspond to H-bond donors and red spheres to H-bond 464 
acceptors 465 
 466 
Fig. 3 Powder X-ray diffractograms of compound 1 solvates (blue: Form A, red: Form B, green: Form 467 
C). 468 
 469 
Fig. 4 Powder X-ray diffractograms of compound 1 acetic acid solvates (blue: Form D-1, red: Form D-470 
2, green: Form D-3, brown: Form D-4). 471 
 472 
Fig. 5 DSC (top) and TGA (bottom) of 1/acetic acid forms. 473 
 474 
Fig. 6 Powder X-ray diffractograms of the new multicomponent forms of compound 1 obtained as a 475 
single form (blue: Form I, red: Form III, green: Form VI, brown: Form VII, purple: Form VIII). 476 
 477 
Fig. 7 Powder X-ray diffractograms of the new forms of 1:3,5-dinitrobenzoic acid (blue: Form II-A, red: 478 
Form II−B, green: Form II−C, brown: Form II-D, purple: Form II-E). 479 
 480 
Fig. 8 Powder X-ray diffractograms of the new forms of 1:orotic acid (blue: Form IV-A, red: mixture 481 
Form IV-A and Form IV−B, green: mixture Form IV-A and Form IV-C). 482 
 483 
Fig. 9 Powder X-ray diffractograms of the new forms of 1:5-nitroisophthalic acid (blue: Form V-A, red: 484 
Form V−B, green: Form V−C, brown: Form V-D, purple: Form V-E). 485 
 486 
Fig. 10 (a) Electrostatic interactions in the sandwiched 1,4,8,11-tetrazacyclotetradecane cation and (b) 487 
ribbons of 1 molecules assembled by charge assisted hydrogen bonds. 488 
 489 
Fig 11 Contacts observed in the crystal structure of acetic acid hybrid salt-cocrystal. 490 
 491 
 492 
Fig. 12 (a) 1 H-bond parameters from DFT calculations and (b) contacts observed in the crystal structure 493 
of DMF solvate 494 
 495 
 496 
Fig. 13 Interactions of 1 in the crystal structure of Form II-A. 497 
 498 
Fig. 14 DSC (top) and TGA (bottom) of 1:3,5-dinitrobenzoic salts. 499 
 500 
Fig. 15 DSC (top) and TGA (bottom) of 1:5-nitroisophthalic acid salts. 501 
502 












































































Table 1 Table 1. Summary of Physicochemical Properties of the Free Base of 1 579 
 580 
 581 
Table 2 Cocrystal Screening Coformers Ranked by ΔE, pKa’sa 582 
 583 
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Table 4. Crystal Data for the Different Crystal Forms of Compound 1 595 
 596 
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